Merck, Plaintiffs Bicker Over Fosamax MDL Wind-Down Plans

Law360, New York (August 19, 2013, 7:56 PM EDT) -- Merck & Co. Inc. and the plaintiffs suing the company over jaw injuries allegedly caused by the bone drug Fosamax proposed competing plans for the wind-down of multidistrict litigation on Monday, with the drugmaker claiming its opponents seek to “dump” the cases across the country.

Merck and the plaintiffs' steering committee sent a joint letter to U.S. District Judge John Keenan outlining their proposals for the transfer of the remaining cases in the litigation, as the judge requested during a status conference last week. He said then that the cases would be sent to their home courts “in the foreseeable future.”...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!